MetaCap

Veraxa Biotech AG Company Profile

NASDAQ: VRXAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.04+0.01 (+0.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Veraxa Biotech at a glance

Veraxa Biotech AG (NASDAQ: VRXA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Zurich, Switzerland. Veraxa Biotech is led by Dr. Christoph Antz Ph.D.. At a market capitalization of $145.7 million, it is considered a small-cap company.

Its SEC Central Index Key (CIK) is 0002079109, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Veraxa Biotech do?

Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Zurich, Switzerland.

Business description based on the company's public filings.

Company information

Legal name
Veraxa Biotech AG
Ticker
NASDAQ: VRXA
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Christoph Antz Ph.D.
Headquarters
Talacker 35, Zurich, Switzerland
Phone
49 6221 3521330
Website
veraxa.com
Market cap
$145.65M
SEC CIK
0002079109

Companies similar to Veraxa Biotech

VRXA peer companies
CompanyPrice% ChgMarket capCompare
BBOTBridgeBio Oncology Therapeutics Inc.1.81-2.69%$145.25Mvs VRXA
PRQRProQR Therapeutics N.V.1.04-0.95%$146.98Mvs VRXA
RNAAtrium Therapeutics Inc.6.92-0.86%$149.27Mvs VRXA
ELDNEledon Pharmaceuticals Inc.1.78-6.32%$150.34Mvs VRXA
IFRXInflaRx N.V.1.04-4.59%$153.26Mvs VRXA
ALXOALX Oncology Holdings Inc.1.06+3.92%$137.03Mvs VRXA
ORMPOramed Pharmaceuticals Inc.3.57-3.25%$155.24Mvs VRXA
ZNTLZentalis Pharmaceuticals Inc.1.360.00%$133.64Mvs VRXA

Related